Moderna gains $45 billion in market value after cancer vaccine breakthrough

Moderna's market value surged by $45 billion on August 19, 2026, after the company and partner Merck & Co. announced that their individualized mRNA cancer vaccine, intismeran, succeeded in a Phase 3 trial for melanoma. The stock spike of over 170% reverses a multiyear slump caused by falling COVID-19 vaccine sales. While some analysts project peak annual sales of $5.4 billion, others caution that the market reaction is overly optimistic given high manufacturing costs and limited disclosed data.

Intismeran Phase 3 trial success

• ▪Moderna Chief Executive Stéphane Bancel announced the melanoma vaccine breakthrough to employees on August 19, 2026, comparing the milestone to the company's COVID-19 vaccine data announcement
• ▪Moderna and Merck & Co. announced on August 19, 2026, that their individualized cancer vaccine, intismeran, succeeded in a Phase 3 trial for melanoma patients
• ▪Moderna and Merck & Co. tested the cancer vaccine intismeran alongside the immunotherapy drug Keytruda in the adjuvant setting following surgical removal of melanoma tumors
• ▪Mid-stage clinical trial data presented at the American Society of Clinical Oncology meeting showed that the combination of intismeran and Keytruda reduced the risk of melanoma relapse or death by approximately half after five years of follow-up
• ▪The individualized cancer vaccine intismeran is designed to stimulate immune responses against 34 unique protein flags, or neoantigens, found on the surface of a patient's tumor

Moderna stock price surge

• ▪Shares of Moderna's partner Merck & Co. and rival vaccine developer BioNTech experienced double-digit percentage gains following the August 19, 2026 trial announcement
• ▪Moderna's share price increased by more than 170% on August 19, 2026, adding approximately $45 billion to the company's market value in a single day
• ▪The August 19, 2026 stock surge followed a multiyear decline where Moderna's share price fell from over $400 to under $30 for much of 2025 due to declining COVID-19 vaccine sales

Analyst revenue projections

• ▪William Blair analyst Myles Minter upgraded Moderna's stock rating and projected that the company could earn $5.4 billion in peak annual melanoma sales from its 50-50 revenue split with Merck & Co
• ▪TD Cowen analyst Tyler Van Buren described the Phase 3 trial results as a significant validation of the underlying mRNA technology, noting the trial was stopped at the first interim data check

Investor skepticism on valuation

• ▪Leerink Partners analyst Daina Graybosch characterized the market reaction as overly optimistic, citing high manufacturing costs for individualized therapies and noting that melanoma is uniquely suited to vaccines
• ▪Evercore ISI analyst Cory Kasimov stated that Moderna's new valuation prices in more conviction than the disclosed data supports, noting that a 20% recurrence risk reduction is the clinical benchmark

Broader cancer trial program

• ▪Mid-stage clinical trial results for the cancer vaccine intismeran in kidney and bladder cancers are expected to be released in late 2026 or in 2027
• ▪Moderna and Merck & Co. are running nine ongoing clinical trials for intismeran, including mid-stage trials in kidney and bladder cancers and a late-stage trial in lung cancer

2 sources